GHRS Stock Analysis: Buy, Sell, or Hold?
GHRS - GH Research PLC Ordinary Shares
$15.66
-0.58 (-3.57%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
24d
Smart Money Accumulation
GHRS is down 6.4% this week, but smart money is accumulating calls. Top strike: $12.5 2026-04-17 with 30 OI. Call ratio: 100% View Scanner →
Strength: 8.2/10
Get Alerted When GHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GHRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GHRS is currently trading at $15.66, which is considered fair relative to its 30-day fair value range of $13.66 to $16.95.
Technical Outlook: Technically, GHRS is in a uptrend. The price is currently testing key support at $15.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.48 (+113.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GHRS is in a uptrend. The price is currently testing key support at $15.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.48 (+113.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$13.66 -
$16.95
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
Protect Your Profits
Holding GHRS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 113.8% below Wall St target ($33.48)
- CAUTION: Recommendation downgraded due to -6.4% 5-day decline
Fair Price Analysis
30-Day Fair Range
$13.66 -
$16.95
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$1.81
(11.6%)
Support & Resistance Levels
Support Level
$15.48
Resistance Level
$17.30
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-10.00
Wall Street Target
$33.48
(+113.8%)
Last updated: February 01, 2026 4:26 AM ET
Data refreshes hourly during market hours. Next update: 5:26 AM
Data refreshes hourly during market hours. Next update: 5:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
Advanced GHRS Option Strategies
Professional options setups generated by AI based on today's GHRS price and gamma walls.
